Inclusion Criteria:

          -  Dose level 1 participants with histologically proven advanced solid tumors, for which
             no effective standard therapy exists, or standard therapy has failed or cannot be
             tolerated

          -  Dose level 1 participants with Eastern Cooperative Oncology Group Performance Status
             (ECOG PS) less than or equal to (<=) 1 and Karnofsky Scale greater than or equal to
             (>=) 70 percent (%)

          -  Dose level 2 and main part participants with ECOG PS <= 2 and Karnofsky Scale >= 60%

          -  Dose level 2 and main part participants with histologically confirmed SCLC

          -  Dose level 2 and main part participants with radiologically confirmed progression
             after first-line or chemoradiation platinum-based treatment (carboplatin or
             cisplatin), with or without immunotherapy, for treatment of limited or extensive stage
             SCLC, with a Platinum-free interval (PFI) less than (<) 90 days. The PFI is measured
             by the elapsed time from the last day of the regimen of a platinum-based treatment
             until the first day of documented disease progression

          -  Dose level 2 and main part participants with measurable disease according to Response
             Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (RECISTv1.1) at Screening.
             Evidence of measurable disease must be confirmed by the IRC prior to start of
             treatment

          -  Tumor tissue provision: archival (collected within 12 months before date of informed
             consent form [ICF]) signature for Screening) or fresh biopsy specimen, if medically
             feasible

          -  Have adequate hematologic and renal function

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Clinically relevant (that is [i.e.], active), uncontrolled intercurrent illness
             including, but not limited to, severe active infection including, severe acute
             respiratory syndrome coronavirus-2 infection/coronavirus disease 2019, immune
             deficiencies, uncontrolled diabetes, uncontrolled arterial hypertension, symptomatic
             congestive heart failure (New York Heart Association Classification greater than or
             equal to [>=] Class III), unstable angina pectoris, myocardial infarction,
             uncontrolled cardiac arrhythmia, cerebral vascular accident/stroke. Calculated
             corrected QT interval (QTc) average (using the Fridericia correction calculation) of
             greater than [>] 450 millisecond (msec) for males and > 470 msec for females. Any
             psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Unstable brain metastases; however, participants with known brain metastases may be
             enrolled in this clinical study if they are clinically stable (without evidence of
             progression by imaging for at least 4 weeks prior to the first study intervention dose
             and any neurologic symptoms have returned to baseline), have no evidence of new brain
             metastases, and are on a stable or decreasing dose of steroids for at least 14 days
             prior to study intervention Participants with carcinomatous meningitis are excluded
             regardless of clinical stability. Screening central nervous system imaging is not
             mandatory

          -  Prior malignant disease within the last 3 years. Exceptions include fully resected
             basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ
             cervical cancer, fully resected ductal carcinoma in situ of the breast, superficial or
             noninvasive bladder cancer, and Stage IA, Grade I endometrioid endometrial cancer with
             no myometrial invasion, that has undergone curative therapy. Participants with other
             localized malignancies treated with curative intent need to be discussed with the
             Medical Monitor

          -  Participants not recovered from adverse events (AEs) Grade > 1 from prior anticancer
             therapies, including surgeries. Exception: Grade 2 AEs not constituting a safety risk
             (for example [e.g.], alopecia), based on the Investigator's judgment; must consult
             with the medical Monitor prior to enrollment.

          -  Other protocol defined exclusion criteria could apply